|
1
|
Sabapathy K and Lane DP: Therapeutic
targeting of p53: All mutants are equal, but some mutants are more
equal than others. Nat Rev Clin Oncol. 15:13–30. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Bykov VJN, Eriksson SE, Bianchi J and
Wiman KG: Targeting mutant p53 for efficient cancer therapy. Nat
Rev Cancer. 18:89–102. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Oren M: Decision making by p53: Life,
death and cancer. Cell Death Differ. 10:431–442. 2003.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Olivier M, Hollstein M and Hainaut P: TP53
mutations in human cancers: Origins, consequences, and clinical
use. Cold Spring Harb Perspect Biol. 2(a001008)2010.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Ryu H, Nam KY, Kim JS, Hwang SG, Song JY
and Ahn J: The small molecule AU14022 promotes colorectal cancer
cell death via p53-mediated G2/M-phase arrest and
mitochondria-mediated apoptosis. J Cell Physiol. 233:4666–4676.
2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Su ZY, Yang ZZ, Xu YQ, Chen YB and Yu Q:
Apoptosis, autophagy, necroptosis, and cancer metastasis. Mol
Cancer. 14:48–61. 2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Elmore S: Apoptosis: A review of
programmed cell death. Toxicol Pathol. 35:495–516. 2007.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Bremer E, van Dam G, Kroesen BJ, de Leij L
and Helfrich W: Targeted induction of apoptosis for cancer therapy:
Current progress and prospects. Trends Mol Med. 12:382–393.
2006.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Makin G and Hickman JA: Apoptosis and
cancer chemotherapy. Cell Tissue Res. 301:143–152. 2000.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Sellers WR and Fisher DE: Apoptosis and
cancer drug targeting. J Clin Invest. 104:1655–1661.
1999.PubMed/NCBI View
Article : Google Scholar
|
|
11
|
Pan ST, Li ZL, He ZX, Qiu JX and Zhou SF:
Molecular mechanisms for tumour resistance to chemotherapy. Clin
Exp Pharmacol Physiol. 43:723–737. 2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Ichim G and Tait SW: A fate worse than
death: Apoptosis as an oncogenic process. Nat Rev Cancer.
16:539–548. 2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Koff JL, Ramachandiran S and
Bernal-Mizrachi L: A time to kill: Targeting apoptosis in cancer.
Int J Mol Sci. 16:2942–2955. 2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Von Karstedt S, Montinaro A and Walczak H:
Exploring the TRAILs less travelled: TRAIL in cancer biology and
therapy. Nat Rev Cancer. 17:352–366. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Aubrey BJ, Kelly GL, Janic A, Herold MJ
and Strasser A: How does p53 induce apoptosis and how does this
relate to p53-mediated tumour suppression? Cell Death Differ.
25:104–113. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Singh R, Letai A and Sarosiek K:
Regulation of apoptosis in health and disease: The balancing act of
BCL-2 family proteins. Nat Rev Mol Cell Biol. 20:175–193.
2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Chen JD: The cell-cycle arrest and
apoptotic functions of p53 in tumor initiation and progression.
Cold Spring Harb Perspect Med. 6(a026104)2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Stegh AH: Targeting the p53 signaling
pathway in cancer therapy-the promises, challenges, and perils.
Expert Opin Ther Targets. 16:67–83. 2012.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Prabhu VV, Allen JE, Hong B, Zhang SL,
Cheng HR and EI-Deiry WS: Therapeutic targeting of the p53 pathway
in cancer stem cells. Expert Opin Ther Targest. 16:1161–1174.
2012.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Joana DA, Joana MX, Clifford JS and
Cecília MP: Targeting the p53 pathway of apoptosis. Curr Pharm
Design. 16:2493–2503. 2010.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Belliotti TR, Brink WA, Kesten SR, Rubin
JR, Wustrow DJ, Zoski KT, Whetzel SZ, Corbin AE, Pugsley TA,
Heffner TG and Wise LD: Isoindolinone enantiomers having affinity
for the dopamine D4 receptor. Bioorg Med Chem Lett. 8:1499–1502.
1998.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Zhuang ZP, Kung MP, Mu M and Kung HF:
Isoindol-1-one Analogues of
4-(2-methoxyphenyl)-1-[2-[N-(2-pyridyl)-p-iodobenzamido] ethyl]
piperazine (p-MPPI) as 5-HT1A receptor ligands. J Med Chem.
41:157–166. 1998.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Kanamitsu N, Osaki T, Itsuji Y, Yoshimura
M, Tsujimoto H and Soga M: Novel water-soluble sedative-hypnotic
agents: Isoindolin-1-one derivatives. Chem Pharm Bull.
55:1682–1688. 2007.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Bernstein PR, Aharony D, Albert JS,
Andisik D, Barthlow HG, Bialecki R, Davenport T, Dedinas RF,
Dembofsky BT, Koether G, et al: Discovery of novel, orally active
dual NK1/NK2 antagonists. Bioorg Med Chem Lett. 11:2769–2773.
2001.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Wacker DA, Varnes JG, Malmstrom SE, Cao X,
Hung CP, Ung T, Wu G, Zhang G, Zuvich E, Thomas MA, et al:
Discovery of
(R)-9-Ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one,
a selective, orally active agonist of the 5-HT(2C) receptor. J Med
Chem. 50:1365–1379. 2007.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Pendrak I, Barney S, Wittrock R, Lambert
DM and Kingsbury WD: Synthesis and anti-HSV activity of
a-ring-deleted mappicine ketone analog. J Org Chem. 59:2623–2625.
1994.
|
|
27
|
Taylor EC, Zhou P, Jennings LD, Mao Hu ZB
and Jun JG: Novel synthesis of a conformationally-constrained
analog of DDATHF. Tetrahedron Lett. 38:521–524. 1997.
|
|
28
|
Hu CM, Zheng LY, Pei YZ and Bai X:
Synthesis of novel 3-aryl isoindolinone derivatives. Chem Res Chin
Univ. 29:487–494. 2013.
|
|
29
|
Hu CM: Design, synthesis and anticancer
activity of novel 3-aryl isoindolinone derivatives. Changchun Jilin
University, 2012.
|
|
30
|
Valente LJ, Aubrey BJ, Herold MJ, Kelly
GL, Happo L, Scott CL, Newbold A, Johnstone RW, Huang DC, Vassilev
LT and Strasser A: Therapeutic response to non-genotoxic activation
of p53 by Nutlin3a Is driven by PUMA-mediated apoptosis in lymphoma
cells. Cell Rep. 14:1858–1866. 2016.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Shah JH, Swartz GM, Papathanassiu AE,
Treston AM, Fogler WE, Madsen JW and Green SJ: Synthesis and
enantiomeric separation of 2-phthalimidino-glutaric acid analogues:
Potent inhibitors of tumor metastasis. J Med Chem. 42:3014–3017.
1999.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Hardcastle IR, Liu J, Valeur E, Watson A,
Ahmed SU, Blackburn TJ, Bennaceur K, Clegg W, Drummond C, Endicott
JA, et al: Isoindolinone inhibitors of the murine double minute 2
(MDM2)-p53 protein-protein interaction: Structure-activity studies
leading to improved potency. J Med Chem. 54:1233–1243.
2011.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Yin C, Knudson CM, Korsmeyer SJ and Van
Dyke T: Bax suppresses tumorigenesis and stimulates apoptosis in
vivo. Nature. 385:637–640. 1997.PubMed/NCBI View
Article : Google Scholar
|
|
34
|
Czabotar PE, Lessene G, Strasser A and
Adams JM: Control of apoptosis by the BCL-2 protein family:
Implications for physiology and therapy. Nat Rev Mol Cell Biol.
15:49–63. 2014.PubMed/NCBI View
Article : Google Scholar
|
|
35
|
DiPaola RS: To arrest or not to G2-M
cell-cycle arrest. Clin Cancer Res. 8:3311–3314. 2002.PubMed/NCBI
|
|
36
|
Yarden RI, Pardo-Reoyo S, Sgagias M, Cowan
KH and Brody C: BRCA1 regulates the G2/M checkpoint by activating
Chk1 kinase upon DNA damage. Nat Genet. 30:285–289. 2002.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Wang WS and Hu YZ: Small molecule agents
targeting the p53-MDM2 pathway for cancer therapy. Med Res Rev.
32:1159–1196. 2012.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Zhao DK, Tahaney WM, Mazumdar A, Savage MI
and Brown PH: Molecularly targeted therapies for p53-mutant
cancers. Cell Mol Life Sci. 74:4171–4187. 2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Deng CX, Zhang PM, Harper JW, Elledge SJ
and Leder P: Mice lacking p21CIP1/WAF1 undergo normal development,
but are defective in G1 checkpoint control. Cell. 82:675–684.
1995.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Taylor RC, Cullen SP and Martin SJ:
Apoptosis: Controlled demolition at the cellular level. Nat Rev Mol
Cell Biol. 9:231–241. 2008.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Wang CX and Youle RJ: The role of
mitochondria in apoptosis. Annu Rev Genet. 43:95–118.
2009.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Su TT: Cellular responses to DNA damage:
One signal, multiple choices. Annu Rev Genet. 40:187–208.
2006.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Bucher N and Britten CD: G2 checkpoint
abrogation and checkpoint kinase-1 targeting in the treatment of
cancer. Br J Cancer. 98:523–528. 2008.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Smith J, Tho LM, Xu N and Gillespie DA:
The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and
cancer. Adv Cancer Res. 108:73–112. 2010.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Sur S and Agrawal DK: Phosphatases and
kinases regulating CDC25 activity in the cell cycle: Clinical
implications of CDC25 overexpression and potential treatment
strategies. Mol Cell Biochem. 416:33–46. 2016.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Mah LJ, El-Osta A and Karagiannis TC:
gammaH2AX: A sensitive molecular marker of DNA damage and repair.
Leukemia. 24:679–686. 2010.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Ola MS, Nawaz M and Ahsan H: Role of Bcl-2
family proteins and caspases in the regulation of apoptosis. Mol
Cell Biochem. 351:41–58. 2011.PubMed/NCBI View Article : Google Scholar
|
